Portage biotech reports results for fiscal year ended march 31, 2025

Dover, del., july 25, 2025 (globe newswire) -- portage biotech inc. (“portage” or the “company”) (nasdaq: prtg), a clinical-stage immuno-oncology company formed under the laws of the british virgin islands, with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today reported its financial results for the fiscal year ended march 31, 2025.

ATON Ratings Summary

ATON Quant Ranking